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27
28 Abstract
29 An important factor for successful translational stroke research is study quality. 
30 Low-quality studies are at risk of biased results and effect overestimation, as has been 
31 intensely discussed for small animal stroke research. However, little is known about the 
32 methodological rigor and quality in large animal stroke models, which are becominge 
33 more frequently used in the field. 
34 Based on research in two databases, this systematic review surveys and analyses 
35 the methodological quality in large animal stroke research. Quality analysis was based 
36 on the Stroke Therapy Academic Industry Roundtable (STAIR) and the Animals in 
37 Research: Reporting In Vivo Experiments (ARRIVE) guidelines. Our analysis revealed 
38 that large animal models are utilized with similar shortcomings than as small animal 
39 models. Moreover, translational benefits of large animal models may be limited due to 
40 lacking implementation of important quality criteria such as randomization, allocation 
41 concealment, and blinded assessment of outcome. On the other hand, an increase of 
42 study quality over time and a positive correlation between study quality and journal 
43 impact factor were identified. 
44 Based on the obtained findings, we derive recommendations for optimal study 
45 planning, conducting and data analysis/reporting when using large animal stroke models 
46 to fully benefit from the translational advantages offered by these models.
47
48
49 Key words: large animal models, stroke, brain ischemia, translational research, 
50 preclinical research, quality guidelines, quality assurance, study validity, predictive 
51 value, bias, study reproducibilitylarge animal, stroke, preclinical research, study quality, 
52 study validity
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53
54 1. Introduction
55 Acute ischemic stroke management and care have profoundly improved with the 
56 introduction of intravenous thrombolysis and, recently, mechanical thrombectomy for large 
57 vessel occlusions.1 However, by far not all patients can benefit from the therapeutic progress 
58 due to numerous contraindications, restricted availability and therapeutic time windows of these 
59 therapeutic approaches. This causes a tremendous need for novel treatment options, but the 
60 translation of preclinical findings into clinically applicable and efficient therapies has so far 
61 been mostly ineffective and prone to failure.2
62 Critical assessment of rodent studies revealed that one important reason for the 
63 translational failure is the lack of methodological quality in these preclinical studies, causing a 
64 higher risk for poor internal validity, overestimation of effect sizes, and biased conclusions thus 
65 affecting rationale and design of subsequent clinical trials.3,4,5
66 Large animal models become more frequently used in preclinical stroke research since 
67 they are believed to provide a number of significant advantages in the translational process.6,7 
68 On the other hand, large animal stroke models are both more laborious and more expensive to 
69 utilize than rodent models. Budgetary limitations often restrict sample sizes in large animal 
70 experiments, what which limits statistical power.8 Hence, it is essential to conduct large animal 
71 experiments with highest methodological rigor and to predefine precise endpoints that can be 
72 assessed with sufficient statistical power in order to take full advantage of the translational 
73 value of large animal stroke models.  
74 Little is known about the methodological rigor and quality of large animal stroke 
75 experiments. We performed a systematic review and quality assessment of studies using large 
76 animal stroke models. Our quality analysis was based on the Stroke Therapy Academic Industry 
77 Roundtable (STAIR)9,10 and Animals in Research: Reporting In Vivo Experiments (ARRIVE) 
78 guidelines.11 Based on the obtained results, we also provide suggestions for methodological 
Page 3 of 68 Journal of Cerebral Blood Flow and Metabolism
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
4
79 improvements in large animal stroke research.
80 2. Material & Methods
81 2.1. Study selection
82          Literature research was performed by the first author (L.K.). L.K. was supported by E.M., 
83 a professional librarian with extensive experience in systematic literature research who helped 
84 with designing the search strategy. The two last authors (S.M. and J.B.) were consulted by L.K. 
85 in case of any doubts or questions when extracting information from the literature. Intra-
86 assessor reproducibility was not assessed.
87
88 2.1.1. Search strategy
89 We conducted a systematic search for preclinical large animal experiments in stroke using 
90 the Medline via Ovid from Wolters Kluwer and Science Citation Index Expanded via Web of 
91 Science from Clarivate Analytics data bases. 
92 The initial search was conducted on September 26th, 2017, and an update was performed 
93 on August 9th, 2019. Data base entries between January 1st, 1990 and August 8th, 2019 were 
94 covered.
95 Search terms were “large animal” (including any relevant species, e.g. dogs, cats, pigs, 
96 rabbits, non-human-primates, sheep, goats, etc.) and “ischemic stroke” (involving for instance 
97 “brain ischemia” OR “ischemic neuronal injury” OR “thrombembolic stroke” OR 
98 “cerebrovascular disorders”). In the search strategies we combined the aspects large aninals 
99 and ischemic stroke with AND. Within each aspect wWe generally combined keywords, their 
100 synonyms and – for indexed citations of MEDLINE – controlled for vocabulary terms (Medical 
101 Subject Headings) using the operator OR. Detailed search strategies are provided in 
102 Supplementary Tables 1 and 2. The search process was conducted and results were recorded 
103 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
104 (PRISMA) guidelines (Figure 1A).
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105
106 2.1.2. Inclusion and exclusion criteria 
107 We included preclinical large animal studies conducted and published between 1990 and 
108 2019 that report investigations of therapeutic and/or diagnostic interventions procedures for 
109 ischemic stroke. The studies needed to compare at least two groups, i.e. one in which a new 
110 procedure (therapeutic or diagnostic) is tested by comparing it to a second group being 
111 subjected to a standard or reference procedure (“control group”). Only studies in English were 
112 included.report a control and an interventional arm. Only studies in English were included.
113 We excluded studies focusing on diseases other than ischemic stroke, using small animal 
114 (e.g., rodent) models, clinical trials, in vitro studies, reviews, and meta-analyses. Purely 
115 descriptive studies only reporting a method or procedure, or non-controlled experiments (e.g., 
116 cases series) were also excluded. 
117
118 2.2. Data extraction
119 2.2.1.Basic study characteristics and impact factor 
120 First, study meta-data were extracted. Those included information on species, type of 
121 intervention, year of publication and region of origin (North America, Europe, Asia & Oceania), 
122 aim of evaluation (e.g., safety, feasibility), the stroke model used, study duration and 
123 information on investigation of dose-response-relationship (if applicable), compliance with 
124 animal welfare regulations, subject health condition prior to enrolment, animal housing 
125 conditions, and additional veterinary care.
126 Second, we documented the journal impact factor (IF) of the journal in which the study 
127 results were published, measured in the year of publication. IFs were identified via the annual 
128 Thomson Reuters Journal Impact Factor report. In caseWhere the IF could not be retrieved for 
129 the required year, we contacted the respective journal and asked to provide the IF for the 
130 particular year(s).
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131
132 2.2.2. Group sizes
133 We further extracted the number of subjects in experimental groups for each species. 
134 Group sizes were obtained for control and the diagnostic or therapeutic procedure group(s). 
135
136
137 2.3. Analysis
138 2.3.1. Assessment of Reporting Quality
139 We designated a scale that was applicable to both, diagnostic and therapeutic procedures, 
140 to assess study quality (Table 1).A score was designed to assess study quality (Table 1). The 
141 quality score includes central STAIR and ARRIVE criteria, supplemented by additional quality 
142 items. The score comprised four categories, containing 6 items each. Category 1 addresses 
143 reporting of study subject details and welfare, category 2 covered the reporting of details on 
144 study design, category 3 addressed internal study validity, and category 4 assessed quality of 
145 outcome analysis and reporting. Each study was assigned a score from 0 (lowest quality) to 24 
146 (highest quality), with each category having a quality value of 0 (lowest quality) to 6 (highest 
147 quality).
148
149 [Table 1 about here]
150
151 2.3.2. Additional aspects influencing study quality 
152 We further investigated whether study quality improved after the implementation of the 
153 STAIR guidelines in 1999, and their update in 2009.9,10 We also analyzed differences in quality 
154 with respect to species, region of study origin, and type of investigation (i.e., assessment of 
155 neuroprotectives, thrombolytics, cell therapies, diagnostics, and others). Furthermore, we 
156 evaluated possible associations between the quality score and impact factor.IF. 
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157
158 2.3.3. Group sizes
159 Where a study reported more than one procedure group, they were all counted 
160 individually (maximum number was n=10). Average group sizes were calculated for control 
161 and procedure groups(s) for each species. We compared total group size (control plus procedure 
162 groups) across species as well as control and procedure groups separately.
163
164 2.4 Statistics 
165 All statistical analyses were performed using GraphPad PRISM 5 Software. Statistical 
166 significance was determined as p<0.05. Statistical significance was indicated with a single 
167 asterisk (*) at p<0.05, or a double asterisk (**) at p<0.01, respectively. Median as well as IQR 
168 (interquartile range including 25% and 75% quartiles) were documented.  Comparisons 
169 between two groups were performed using the Wilcoxon signed rank test for non-parametric 
170 data to conservatively account for relatively small sample sizes. In case more than two groups 
171 were compared, the Kruskal-Wallis test was used, followed by Dunn`s correction for multiple 
172 comparisons. Spearman’s correlation analysis was performed to evaluate associations between 
173 quality score and impact factor.IF. Group sizes were analyzed by ANOVA on ranks (no normal 
174 distribution of data) followed by Dunn's multiple comparison test.
175
176 3. Results 
177 3.1. Data set and year of publication
178 Initial and update searches identified a total of 10282 manuscripts being reduced to 8093 
179 after elimination of duplicates. (Figure 1A; a list of all studies included can be found in the 
180 supplementary material). A total of 2089 studies were included in final analysis after screening 
181 abstracts and full text according to preset inclusion and exclusion criteria (Figure 1A). Results 
182 of basic study characteristics are shown in Table 2.
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183 Analysis of publication output per year revealed that the number of large animal 
184 experiments published from 1990 to 2014 generally decreased from n=56 in 1990-1994 to n=21 
185 in 2010-2014 (Figure 1B). However, there was a steep increase in published studies from 2015, 
186 reaching an all-time high (n=40) even though studies published in late 2019 are not yet included 
187 in our search strategy. This might be related to the milestone evidence for clinical benefit 
188 publication of mechanical thrombectomy in large vessel occlusion stroke by the publication of 
189 five randomized controlled trials in 2015 that may have sparked new interest in the field and an 
190 increased demand for large animal models to investigate related procedures.12,13Analysis of 
191 publication output per year revealed that the number of large animal experiments published 
192 from 1990 to 2019 generally decreased after reaching a peak in the mid 1990s (Figure 1B). 
193 There were more publications in the 1990s (n=93) than in the last decade (n=62). However, 
194 publication output remarkably increased since 2014 with 47 studies published between 2014 
195 and 2019.
196
197 [Figure 1 about here]
198 [Table 2 about here]
199
200 3.2. Study Quality
201 The overall median quality score was 112 (range 3 to 22; IQR: 4 (9-13)) out of 24. The 
202 median quality score in the first category (reporting of study subject details and welfare) was 2 
203 out of 6 (range 1 to 5; IQR: 1 (1-2)). The second category (study planning quality) also reached 
204 a median quality score of 2 (range 1 to 6; IQR: 1 (2-3)). The third category (study conductance 
205 quality) had a median score of 3 (range 0 to 6; IQR: 2 (2-4)). Category 4 (result reporting and 
206 analysis quality) had a median quality score of 4 (range 0 to 6; IQR: 1 (23-4)). A significantly 
207 lower number of quality criteria were fulfilled in category 1 in comparison to the others 
208 (p<0.05).
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209
210 3.2.1. Study subject details and welfare (category 1)
211 All studies reported the species used, but only 146 studies (70.269.9%) reported that the 
212 study was approved by responsible animal welfare authorities. Sex and age were reported by 
213 31 studies (15.04.8%). Sex only was reported by 153 (73.62%), while age was not reported 
214 solely. The pre-study health status was reported by only 12 studies (5.87%). Medication details 
215 including the use of companion medication (e.g., analgetics, antibiotics) was reported in only 
216 20 studies (9.6%). Comorbidities were not reported by any study.
217
218 3.2.2.Study planning (category 2)
219 Working hypotheses were reported in 2078 (99.5%) studies. However, primary study 
220 endpoints were nominally determined in only 10 studies (4.8%). 135 (64.6%) studies reported 
221 that the study rationale was based on earlier small animal (n=79; 38.07.8%) or in vitro studies 
222 (n=256; 12.14%), or both (n=16; 7.7%). Effect size estimation and a priori sample size 
223 calculation can be performed based on such data. However, only 27 studies (13.02.9%) actually 
224 reported an estimation of effect size and a priori sample size calculation. A specific primary 
225 working hypothesis explicitly referring to previous in vitro and/or in vivo studies was reported 
226 in 18 studies (8.76%). Inclusion and exclusion criteria were reported in 104 studies 
227 (49.850.0%), but only 2 studies (1.0%) determined these criteria a priori.
228
229 3.2.3.Study conductance (category 3) 
230 Randomization was reported in 116 studies (55.85%), and allocation concealment was 
231 reported in 59 cases (28.42%). 104 studies (4950.0.8%) reported blinded outcome assessment. 
232 Measurement of physiological parameters was reported in 1656 cases (79.34%). The most 
233 frequently monitored parameters included mean arterial pressure (systemic), temperature, 
234 blood gases, blood pH, and exhalation gases. 1867 studies reported appropriate outcome 
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235 analysis modalities (89.45%; information on inappropriate analysis modalities are provided in 
236 Supplementary Table 3). These included survival rate (n=2; 1.0 %), functional outcome (n=67; 
237 32.2%), infarct size (n=46; 22.1%, as determined by appropriate methods such as imaging or 
238 histology), other imaging (n=90; 43.3%) or histology (n=61; 29.3%) endpoints, clinical 
239 chemistry (n=52; 25.0%), general pathology (n=24; 11.5%) or both (n=18; 8.7%)These 
240 included survival rate (n=2; 1.0 %), functional outcome (n=67; 32.1%), imaging endpoints 
241 (n=91; 43.6%), clinical chemistry (n=52; 24.9%), general pathology (n=24; 11.5%) or histology 
242 (n=61; 29.2%) or both (n=18; 8.6%), as well as infarct size (n=46; 22%) as determined by 
243 appropriate methods such as imaging or histology. Only a fraction of studies that recorded 
244 physiological parameters finally analyzed those (n=52; 24.925.0%). 100 studies (48.17.8%) 
245 reported verification of infarct induction during intervention.
246
247 3.2.4.Result reporting and analysis (category 4)
248 1689 studies (80.89%) adequately reported relevant data and findings in form of detailed 
249 tables or graphs. However, data were almost exclusively reported as means or medians. 
250 Individual data points were only provided by 167 studies (7.78.1%). Drop outs and excluded 
251 subjects were reported in 105 studies (50.52%). Application of appropriate statistical tests was 
252 reported in 1923 studies (92.3%). 16 studies incompletely reported statistical analysis and, for 
253 instance example lacking information regarding statistical tests applied including post hoc tests. 
254 91 studies (43.85%) described potential sources of error and bias in the experiment, while 115 
255 (55.30%) reported limitations such as small sample size or impossibility that it was impossible 
256 to perform randomization. A conclusion fully justified by study findings was given in by most, 
257 but not all reports (n=1901; 91.34%).
258
259 3.3. Additional influences on study quality
260 3.3.1. Study quality versus origin, species and type of intervention
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261 Total median quality score was highest in studies from North America (Median: 121; 
262 IQR: 5.75 (8.25-1410-14)), but not statistically different from studies conducted in Asia & 
263 Oceania (Median: 10; IQR: 3.25 (8.75-12)) as well as those fromor  Europe (Median: 10; IQR: 
264 3.75 (8-11.75; )) (p=0.1516 0011 Figure 2A). Analysis of individual quality categories revealed 
265 no differences in category 1 (Figure 2B) but North American studies had statistically 
266 significantly higher scores in quality categories 2 (Median: 2.5; IQR: 2 (2-3)) and 3 (Median: 
267 4; IQR: 2 (3-5)) than their European counterparts (Median: 2; IQR: 1-2; p<0.01; Figure 2C). In 
268 the second category, North American studies performed better than their European counterparts 
269 (Median: 2; IQR: 1 (1-2)) (p<0.01; Figure 2C). Furthermore, North American studies were 
270 superior to Asian & Oceanian studies in category 3 (Median 3; IQR: 2 (2-4); ) (p<0.01; Figure 
271 2D). We did not find statistically significant differences regarding category 4 (Figure 2E). 
272 Quality scores were neither influenced by species used (Figure 2F) nor by the types of 
273 intervention (Figure 2G). Overall differences in median quality score in species varied 
274 significantly without any specific intergroup difference. 
275
276 [Figure 2 about here]
277
278 3.3.2. Study quality in the post-STAIR era
279 MIn general, methodological quality significantly improved after publication introduction of 
280 the first STAIR guidelines in 1999 (1990-1999 pPre-STAIRtair mMedian: 10, IQR: 4 (8-12); 
281 pPost-STAIRStair mMedian: 12, IQR: 6 (9-15); p<0.01; Figure 2H). We also compared quality 
282 scores of studies published prior to the first STAIR guidelines to quality scores of studies 
283 published(1990-1999; Median: 10, IQR: 4 (8-12)), in the time between the first STAIR 
284 guideline publication and the 2009 update (2000-2009; mMedian: 11; IQR: 4 (9-13)), and to 
285 scores of studies published after the STAIR preclinical guideline2009 update (2010-2019; 
286 mMedian: 132.50; IQR: 5 (10-15)). Quality scores of studies published after the STAIR 2009 
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287 update were higher than those of studies published before the initial STAIR guideline 
288 publication (1990-1999; p<0.01). They were also higher than quality scores of studies published 
289 after the first publication of STAIR guidelines and prior to the 2009 update (2000-2009; p<0.05; 
290 Figure 2I).We found significantly higher quality in studies conducted between 2010-2019 
291 compared to those performed prior STAIR guideline publication (1990-1999; p<0.01) and those 
292 performed after the first publication of STAIR guidelines (2000-2009; p<0.05; Figure 2I). 
293 Improvements were particularly evident in categories 1 and 4.  In category 1, quality 
294 scores were lower in pre-STAIR studies (1990-1999; median: 1, IQR: 1-2) as compared to 
295 studies published after the first publication of STAIR guidelines and prior to the 2009 update   
296 (2000-2009; median: 2; IQR: 1.25-2) and to studies published after the 2009 update (2010-
297 2019; median: 2; IQR: 2-3; p<0.01). There was also a significant difference in category 1 
298 quality scores of studies published after the 2009 update to studies published between 2000 and 
299 2009 (p<0.01).  In category 4, quality scores of studies published after the 2009 STAIR update 
300 (2010-2019; median: 4; IQR: 3-5) were higher than those of studies published before the STAIR 
301 guidelines introduction (1990-1999; median: 3; IQR: 2-4) and those of studies published 
302 between 2000 and 2009 (median 3; IQR: 2-4; p<0.01 each). 
303 (1990-1999 (Median: 1, IQR: 1 (1-2)) vs. 2000-2009 (Median: 2; IQR: 0.75 (1.25-2)) and 1990-
304 1999 vs. 2010-2019 (Median: 2; IQR: 1 (2-3)) and 2000-2009 vs. 2010-2019 (p<0.01)) and 4 
305 (1990-1999 (Median: 3; IQR: 2 (2-4)) vs. 2010-2019 (4; IQR: 2 (3-5)) and 2000-2009 (Median 
306 3; IQR: 2 (2-4)) vs. 2010-2019) (p<0.01). 
307
308 3.3.3. Study quality versus impact factor
309 The IF was documented available for 1723 studies (82.78%). We could not retrieve the 
310 IF for the remaining studies or no IF yet assigned on the particular journal in the year of 
311 publication (n=36; 17.32%). These latter studies were therefore excluded from the following 
312 analyses. Median IF was 3.3 (range 0.1 to 41.6; IQR: 2.65 (2-4.65)). Correlation analysis 
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313 showed a statistically significant positive relationship between the total quality score and the 
314 journal impact factorIF (r=0.27232802; p<0.01, alpha=0.05; Figure 3). We also correlated each 
315 quality score category with the IF and found that quality scores in all individual categories 
316 positively correlated with the IF (category 1: r=0.19181851; p<0.05; category 2: r=0.165317; 
317 p<0.05; category 3:  r=0.1858769; p<0.05; category 4: r=0.2297185; p<0.01; Supplementary 
318 Figure 1). 
319
320 Figure 3 about here
321 3.3.4. Group sizes
322 Average group sizes across species are given in Table 3. Analysis of group sizes 
323 revealed that total (combined control and procedure) group size was largest in rabbits as 
324 compared to pigs (p<0.01), sheep and primates (p<0.05 each). Total group sizes in cats were 
325 larger than those in sheep (p<0.05; Figure 4A). Accordingly, control groups were largest in 
326 rabbits as compared to pigs (p<0.05) and primates (p<0.01; Figure 4B), while procedure groups 
327 were largest in rabbits as compared to pigs (p<0.01; Figure 4C).    
328
329 [Table 3 about here]
330 [Figure 4 about here]
331
332 4. Discussion
333 Systematic bias may cause over- or underestimation of study results.3 Quality items such 
334 as randomization, allocation concealment, and blinded assessment help to improve internal 
335 validity 142, but are often neglected in small animal studies.3, 153, 164
336 Large animal models are believed to offer significant benefits for translational stroke 
337 research. Those comprise aThey have  higher anatomical similarity to the human brain175 and 
338 to the cerebrovascular systemcerebrovascular system anatomy.6, 7, 186 Another benefit is the 
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339 potential to use these models in experiments closely mimicking a human clinical situation, and 
340 applying the same medical techniques and equipment for diagnostic and therapeutic 
341 interventions that would be used in human patients.7, 197 Moreover, physiological characteristics 
342 of large animal models including heart and respiratory frequency, blood pressure as well as 
343 pharmacodynamic and pharmacokinetic profiles are similar to humans.2018, 2119 However, in 
344 view of these advantages, large animal studies require much greater efforts and resources. It is 
345 therefore important that quality in large animal studies is as high as possible to efficiently utilize 
346 the advantages large animal models offer for translational research.
347 Overall, we found that methodological quality in large animal stroke studies was 
348 mediocre. Although quality generally improved significantly over the last decades and 
349 potentially due to the 1999 publication and 2019 update of the STAIR criteria, our analysis 
350 revealed some important shortcomings. Improvements are needed in reporting study subject 
351 details and welfare (quality score category 1). Aspects such as sex and age, pre-study health 
352 conditions, and medications should be reported routinely for optimal study transparency and 
353 reproducibility, and transferability of study results.9 The lack of comorbid large animal models 
354 is not surprising. Comorbidities are difficult to simulate in outbred large animal models as they 
355 occur due to age, distress, malnutrition and other factors according to the human 
356 situationComorbidities may hardly be mimicked in outbred large animal models as they occur 
357 due to age, distress, malnutrition and other factors according to the human situation, and can 
358 take significant time in large animals to develop. Research on models exhibiting comorbidities 
359 may remain a domain of small animal research. Nevertheless, any spontaneously occurring 
360 comorbidities being diagnosed in large animals used for research should be reported.
361 Working hypotheses were reported in almost all studies (99.5%), but often without any 
362 obvious influence on study design. For instance, only 4.8% of the studies defined and reported 
363 primary endpoints, while analysis of expectable effect size and a priori sample size calculation 
364 were performed in few cases only (132.0%). This may severely limit the translational benefits 
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365 of large animal models since neutral studyies results may be hard to interpret based on 
366 potentially poor statistical power. Given the significant resources required to perform large 
367 animal studies, considering these aspects is essential. On the other hand, determination of effect 
368 size can be challenging when previous research data is lacking or not entirely applicable. In 
369 these cases, we recommend to perform large animal pilot studies that may help to assess basic 
370 characteristics in the respective model, such as variability of stroke infarct size and its impact 
371 on the envisioned primary endpoint.
372 While almost two thirdshalf of the studies reported inclusion and exclusion criteria 
373 (64.650.0%), almost none (1.01%) applied them a priori. Defining inclusion and exclusion 
374 criteria during or after the study is believed to be a major source of bias, particularly when a 
375 study is conducted in non-unblinded fashion. Hence, such bias can unfortunately not be 
376 excluded for most studies we analyzed. 
377 Important quality aspects such as randomization (55.85%), allocation concealment 
378 (28.42%), and blinded assessment of outcome (49.750.0%) were more frequently reported in 
379 large animal studies as compared to small animal stroke experiments (randomization: 33.3%; 
380 blinded assessment of outcome: 44.4%,164 allocation concealment: 25.9%; randomization, 
381 allocation concealment and blinded assessment of outcome: 24.1.%.220 Nevertheless, the 
382 number of studies not reporting those is still remarkably high in particular since blinding and 
383 randomization shouldall be minimum standard quality assurance procedures in confirmative 
384 stroke research231 to which almost all large animal studies aim to contribute.
385  Imaging techniques such as magnetic resonance imaging, computed tomography, and 
386 angiography (43.5%) as well as physiological monitoring (80.4%) were utilized relatively 
387 frequently. This is a positive aspect since large animals are particularly suitable for clinical 
388 imaging techniques while thorough physiological monitoring creates meaningful information 
389 that may warrant subject in- or exclusion. However, verification of infarct induction (only 
390 reported in 47.848.1%) as well as infarct size should be conducted thoroughly and routinely to 
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391 avoid the risk of increasing inter-subject/-study/-group variability, further reducing statistical 
392 power of an experiment. Parameters such as reduced cerebral blood flow reduction for 
393 verification of infarct induction was documented by only 7.2% of studies. This is surprising 
394 since these parameters are relatively easy to determine in large animals, while clinical imaging 
395 techniques may be used to confirm the induced lesion directly.2119
396 Large animals are suitable for long-term studies including functional endpoint 
397 assessment. However, we only found a relatively low percentage (6.7%) of studies being 
398 conducted for more than one month, the minimum follow-up period recommended by the 
399 STAIR guidelines for functional endpoints. Next to costs, tThis may be due to the selection of 
400 other primary endpoints such as safety or efficacy of recanalization methods which can be 
401 assessed more rapidly. However, experimenters who wish to assess behavioral endpoints 
402 should take into consideration that functional consequences of stroke in large animals can be 
403 more heterogeneous than in rodent models, and may develop over longer time spans.242
404 We recognized significant improvements in methodological quality since the publication 
405 of the first STAIR guidelines in 1999, and in particular after the STAIR guideline update in 
406 2009. Comparable improvements were reported for small animal stroke studies from 2010 to 
407 2013.253 These findings indicate the positive impact of specific good research practice 
408 guidelines, which should be advanced continuously as evidenced by the recent 2019 STAIR 
409 guideline updates.264 In contrast to previous findings in small animal studies,275 we also 
410 identified positive association (r=0.27232802; p<0.01) between study quality and publication 
411 in high-impact journals. In particular, total quality score as well as quality scores in all single 
412 categories 1-4 significantly correlated with higher IF. This is an encouraging result since all 
413 these categories include items being important to prevent bias. These items are hence essential 
414 indispensable for a valid and transparent exchange of information between researchers. 
415           Group sizes were significantly larger in rabbits as compared to other species. This is not 
416 surprising as rabbits are the smallest and cheapest of all large animal species what allows for 
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417 larger group sizes. Importantly, group sizes in primates are generally not different to that of 
418 other species. This does not mean that group sizes were sufficient for each research question, 
419 but shows that costs related to primate experiments did not prevent the same group sizes as seen 
420 in other large animal species despite rabbits.
421 Our study has a number of limitations. We applied a predefined search strategy and 
422 protocol being developed together an expert in literature meta-analyses (E.M.) and experts in 
423 stroke research (J.B., S.M.). However, search strategy and protocol were not registered (ex ante 
424 protocol). Data extraction was not done in duplicates, but senior experts were consulted in all 
425 doubtful cases. Intra-assessor reproducibility was not assessed. Moreover, we did not 
426 discriminate between studies focusing on therapeutic and diagnostic procedures. Large animal 
427 models provide a number of benefits over rodent models for diagnostic studies due to the larger 
428 brain size and in particular when clinical imaging is used.33 However, those studies are often 
429 exploratory in nature. Since quality demands are different (and a bit lower) than in confirmative 
430 studies, those imaging-related studies would perform normally worse but still can contribute 
431 invaluably to their respective field.34 Finally, we did not include a number of insightful imaging 
432 studies because they did not conduct a formal inter-group comparison.35,36,37,38
433
434 5. Conclusions and Recommendations
435 Although large animal models offer a offer a number of clear advantages for translational 
436 strokeclear benefit in many translational stroke studies, we found that they are utilizedhave with 
437 similar shortcomings than to small animal models, limiting this benefitthis benefit. 
438 HenceTherefore, we derived a number of recommendations that may overcometo address these 
439 limitations but are, at the same time, relatively easy to implement.
440
441 5.1 Study planning and preparation
442 Large animal stroke studies are mostly confirmative studies. HenceTherefore, study 
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443 planning should be based on high quality standards applied for randomized controlled clinical 
444 trials (RCTs) when possible. Key elements of RCT planning and design such as a priori sample 
445 size calculation and endpoint definition should be conducted.231 We encourage to involve 
446 statisticians already in early planning stepsStatisticians may be involved already in early 
447 planning steps to optimize study design.286 Study planning can also be supported by specific 
448 software tools. For instance, the National Centre for the Replacement, Refinement and 
449 Reduction of Animals in Research provides a freeware called Experimental Design Assistance 
450 (https://eda.nc3rs.org.uk), which is free to use and was built to guide researchers through their 
451 study planning.297 Since optimal sample sizes may not be achieved for all endpoints, it is 
452 important to clearly define the most appropriate primary study endpoint, and to power the study 
453 properly. Collaboration between research teams in form of peer quality checks and validation 
454 of study design can highly increase objectivity and validity of a study.3028 Inter-group 
455 collaboration and transfer of experience can also help to handle very complex models and/or 
456 experimental setups, helping to reduce inter-subject variability negatively affecting statistical 
457 power. Confirmative studies might be preregistered to maximize transparency.39 
458
459 5.2 Effect size estimation and pilot trials
460 Collecting valid information from previous research is essential for reliable effect size 
461 estimation. If such data is are not available, pilot studies may be helpful for at least basically 
462 estimating variability of stroke impact and outcome in the model. In case previous experience 
463 with a particular model is low, variability is more likely to be overestimated higher and effect 
464 size is more likely to be underestimated fromlower in such pilot trials. , contributing to This 
465 will contribute to more conservative study planning since sample sizes calculated based on that 
466 information will be higher. conservative study planning. An important side effect of pilot trials 
467 is experimenter training which limits experimenter-caused endpoint variability (see below) in 
468 the main experiment. In addition, meta-analyses can help to collect relevant information on 
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469 effect size or regarding a specific research question from related fields.3129
470
471 5.3 Reducing the effect of sample size limitations and endpoint variability
472 Financial and logistical restrictions often impact sample and group sizes in large animal 
473 experiments. This is an understandable limitation which is hard difficult to overcome. Selection 
474 of a proper and relevant endpoint that can be adequately powered with respected to the 
475 addressed research question (not necessarily functional outcome) is therefore important to 
476 minimize the risk for low statistical power. Of note, some endpoints often used in studies 
477 assessing therapeutic interventions, including infarct size and functional deficits, exhibit a 
478 higher variability in large animal models than in rodent ones. , making This makes comparison 
479 of absolute data more difficult.242 Relative analysis of repeatedly assessed endpoints, i.e. in 
480 comparison to the individual initial infarct size and/or functional deficit can efficiently 
481 compensate for such variability, allows to efficiently compensate for such variability. Repeated 
482 assessments also allow calculating the area under the curve for particular endpoints. This may 
483 provide a benefit in statistical power to identify whether a real outcome benefit is present over 
484 time. However, this comes at the cost of temporal resolution: it cannot be concluded exactly 
485 when this benefit became evident. There is also preliminary evidence for fast and slow stroke 
486 progressors in large animals, indicating different collateral status and somewhat resembling the 
487 human situation, but further contributing to inter-subject variability. It is recommended to 
488 consider this fact when planning an acute stroke study.320
489 In experiments of highly similar design, controls may be pooled. Of note, this counteracts 
490 randomization and therefore requires extremely thorough validation of comparability of control 
491 subjects from different experiments/sources. If comparability is thoroughly proven, this may 
492 help to increase statistical power, but the limitations of this approach and potentially resulting 
493 bias need to be discussed transparently and in detail when publishing results. 
494 The possibility to repeatedly collect a broad spectrum of physiological data should be 
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495 utilized to the bestwhere possible extend, as deviation from normal parameter ranges may 
496 explain variability and warrant post-hoc exclusion of subjects in single cases.
497
498 5.4 Study duration and documentation
499 We recommend considering long-term experiments whenever meaningful and possible 
500 and meeting animal welfare requirements. Even though long-term experiments involve greater 
501 efforts, the amount of data collected for individual subjects may be much higher, providing a 
502 better overall picture on the assessed intervention. Documentation should be as transparent as 
503 possible since because transparency is not challenging or laborious, but contributes 
504 significantly to increased scientific rigor, reproducibility, and unbiased study result 
505 interpretationat all. Methodological limitations including lacking quality aspects due to good 
506 reason should be clearly stated as this allows better interpretation of positive, neutral and 
507 negative study results. 
508
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631 39. Kimmelmann J and Anderson JA. Should preclinical studies be registered? Nat 
632 Biotechnol 2012; 30(6): 488-489.
633
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636 Figure legends
637 Figure 1. Overview on quantitative search results and frequency of large animal 
638 experiments in stroke research since 1990.
639 (A) Flow diagram of publication identification. N = Number of publications. Records 
640 were excluded after screening title and abstracts. Full-text articles were then screened and 
641 excluded for a priori determined reasons. (B) Timeline of publication in large animal stroke 
642 research (1990-2019): The increase of large animal stroke studies in the last years is potentially 
643 due to the breakthrough in recanalization therapies, prompting a number of follow-on 
644 translational studies utilizing large animal stroke models.
645
646 Figure 2. Influence of study origin and STAIR criteria publication on study quality. 
647 (A) Total quality score, (B) Category 1: Reporting of study subject and animal welfare, 
648 (C) Category 2: Study planning quality (North America vs. Europe p<0.01), (D) Category 3: 
649 Study conductance quality (North America vs. Asia & Oceania p<0.01), (E) Category 4: Result 
650 reporting and analysis quality (North America vs. Europe p<0.01), (F) Improvement in total 
651 methodological quality since the publication of the first STAIR criteria in 1999 
652 (p<0.01),Influence of species, (G) Improvement in total methodological quality since the 
653 publication of the first STAIR criteria comparing to their amendment in 1999 (2010-2019 vs. 
654 1990-1999 p<0.01), and 2010-2019 vs. 2000-2009 p<0.05), (H) Improvement in total 
655 methodological quality since the publication of the first STAIR criteria in 1999 comparing to 
656 their amendment in 2009 (2010-2019 vs. 1990-1999 p<0.01, and 2010-2019 vs. 2000-2009 
657 p<0.05),  Influence of species, (I) Influence of type of intervention. Horizontal lines and 
658 whiskers indicate the medianan with lower and upper 95% CI. *p<0.05; **p<0.01.
659
660 Figure 3. Association between total quality score versus impact factor.
661 Scatterplot shows correlation between quality score and impact factor IF (p<0.01). 
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662 Number of included studies is 1723, no IF could be retrieved for 36 studies. The latter studies 
663 were excluded from this analysis.
664
665 Figure 4. Group sizes across species.
666          (A) Total group sizes were largest in rabbits as compared to pigs (p<0.01), primates and 
667 sheep (p<0.05 each). (B) Control group sizes were larger in rabbits as compared to primates 
668 (p<0.01) and pigs (p<0.05). (C) Procedure group sizes were larger in rabbits as compared to 
669 pigs (p<0.01). Horizontal lines and whiskers indicate the median with lower and upper 95% CI. 
670 *p<0.05, **p<0.01.
671
672
673 Tables
674 Table 1. Quality score items. 
Category 1: Reporting of study subject 
details and welfare
Category 2: Study planning quality
Item Score point 
allocation
Item Score point 
allocation
1. Animal protocol 
approved
Reported 
yes=1/no=0
1. Study hypothesis Reported 
yes=1/no=0
2. Species Reported 
yes=1/no=0
2. A priori endpoint 
definition
Reported 
yes=1/no=0
3. Sex and Age Reported 
yes=1/no=0
3. A priori sample size 
calculation
Reported 
yes=1/no=0
4. Pre-Study Health Reported 
yes=1/no=0
4. Reference to previous 
studies
Reported 
yes=1/no=0
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5. Comorbidities Reported 
yes=1/no=0
5. Inclusion/Exclusion 
criteria
Reported 
yes/no=0
6. Adequate 
medication
Reported 
yes=1/no=0
6. Effect size/Treatment 
effect
Reported 
yes=1/no=0
Category 3: Internal study validity Category 4: Outcome analysis and 
reporting
Item Score point 
allocation
Item Score point 
allocation
1. Blinding Reported 
yes=1/no=0
1. Individual data points Reported
yes=1/no=0
2. Randomization Reported 
yes=1/no=0
2. Drop outs/Excluded 
subjects
Reported 
yes=1/no=0
3. Allocation 
concealment
Reported 
yes=1/no=0
3. Appropriate statistical 
tests
Used 
yes=1/no=0
4. Physiological 
parameters
Measuring reported 
yes=1/no=0
4. Potential error sources Reported 
yes=1/no=0
5. Analysis 
modalities
Appropriate 
modalities reported# 
yes=1/no=0
5. Study/Methodological 
limits
Reported 
yes=1/no=0
6. Infarct induction 
confirmation
Reported 
yes=1/no=0
6. Justified conclusion 
given##
Provided 
yes=1/no=0
675 #analysis modalities were considered appropriate when being sufficient to assess the 
676 respective research question or endpoint (see Supplementary Table 3 for details).
677 ##conclusion was considered justified when supported by correctly analyzed results.
678
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679
680 Table 2. Basic Characteristics of included Animal Experimental Studies.
Item Frequency (%) Item Frequency (%) Item Frequency (%)
Species Type of intervention Study duration
Rabbit n=96 (45.946.1%) Neuroprotectives n=113 (54.31%) Acute phase (<24h) n=13940 (67.066.9%)
Cat n=43 (20.76%) Thrombolytics n=52 (24.925.0%) 1-3 days n=26 (12.54%)
Dog n=16 (7.7%) Cell therapies n=78 (3.83.4%) <1 week n=15 (7.2%)
Non-Human-Primate n=32 (15.43%) Diagnostics n=15 (7.2%) <1month n=14 (6.7%)
Pig n=1920 (9.16%) Others# n=21 (10.10%) >1 month n=14 (6.7%)
Non-Human-Primate & 
Rabbit
n=1 (0.5%)
Sheep n=1 (0.5%)
Region Primary endpoint Stroke model
North America n=1345 (64.46%) Efficacy n=162 (77.95%) Transient n=120 (57.74%)
Europe n=24 (11.5%) Safety n=12 (5.87%) Permanent n=767 (36.58%)
Asia/Oceania n=50 (24.13.9%) Feasibility n=223 Transient +Permanent n=1 (0.5%)
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(11.010.5%)
Safety + 
Feasibility
n=1 (0.5%) Not reported n=11 (5.3%)
Safety + Efficacy n=11 (5.3%)
Further information
Additional veterinary care 
reported 
n=11 (5.3%)
Dose-response 
relationship reported
n=30 (14.4%)
Compliance with animal 
welfare regulations 
reported 
n=128 (61.52%)
Pre-study quarantine 
reported
n=3 (1.4%)
Animal housing 
conditions## reported
n=23 (11.10%)
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681 #these included hypothermia (n=7), hemodilution (n=5), facial nerve stimulation (n=2), hyperglycemia, retrograde transvenous perfusion, crosslinked 
682 hemoglobin transfusion, alkalinization of systemic pH, omental transposition, induced hypertension, RIPC (short term remote ischemic 
683 postconditioning) (n=1 each)
684 ##e.g., feeding, light/dark circle, single or grouped housing
685
686 Table 3. Median experimental group sizes across large animal species.
Non-human primate Rabbit Dog Cat Sheep Pig
C P T C P T C P T C P T C P T C P T
7.4
(1-24) 
n=35
6.3
(2-17) 
n=64
6.6 
(1-24) 
n=99
12.4 
(2-50) 
n=108
10.0 
(2-57) 
n=267
11.0 
(2-57) 
n=375
7.1 
(5-10) 
n=15
9.0
(1-16) 
n=25
8.3 
(1-16) 
n=40
8.7
(2-17) 
n=45
8.6 
(3-18) 
n=77
8.6 
(2-18) 
n=122
6 
(6) 
n=1
4.25 
(3-6) 
n=4
4.2 
(3-6) 
n=5
5.8
(2-11) 
n=16
6.4
(1-10) 
n=45
6.2 
(1-11) 
n=60
687 C: control group; P: procedure group(s); T: total (combined) groups. Ranges (min.-max.) are given in brackets. n describes numbers of groups 
688 throughout the included literature.
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Running headline: Role and analysis of methodological quality in large animal experiments in 
stroke
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Abstract
An important factor for successful translational stroke research is study quality. Low-
quality studies are at risk of biased results and effect overestimation, as has been intensely 
discussed for small animal stroke research. However, little is known about the methodological 
rigor and quality in large animal stroke models, which are becoming more frequently used in 
the field. 
Based on research in two databases, this systematic review surveys and analyses the 
methodological quality in large animal stroke research. Quality analysis was based on the 
Stroke Therapy Academic Industry Roundtable (STAIR) and the Animals in Research: 
Reporting In Vivo Experiments (ARRIVE) guidelines. Our analysis revealed that large animal 
models are utilized with similar shortcomings as small animal models. Moreover, translational 
benefits of large animal models may be limited due to lacking implementation of important 
quality criteria such as randomization, allocation concealment, and blinded assessment of 
outcome. On the other hand, an increase of study quality over time and a positive correlation 
between study quality and journal impact factor were identified. 
Based on the obtained findings, we derive recommendations for optimal study planning, 
conducting and data analysis/reporting when using large animal stroke models to fully benefit 
from the translational advantages offered by these models.
Key words: large animal, stroke, preclinical research, study quality, study validity
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1. Introduction
Acute ischemic stroke management and care have profoundly improved with the 
introduction of intravenous thrombolysis and, recently, mechanical thrombectomy for large 
vessel occlusions.1 However, by far not all patients can benefit from the therapeutic progress 
due to numerous contraindications, restricted availability and therapeutic time windows of these 
therapeutic approaches. This causes a tremendous need for novel treatment options, but the 
translation of preclinical findings into clinically applicable and efficient therapies has so far 
been mostly ineffective and prone to failure.2
Critical assessment of rodent studies revealed that one important reason for the 
translational failure is the lack of methodological quality in these preclinical studies, causing a 
higher risk for poor internal validity, overestimation of effect sizes, and biased conclusions thus 
affecting rationale and design of subsequent clinical trials.3,4,5
Large animal models become more frequently used in preclinical stroke research since 
they are believed to provide a number of significant advantages in the translational process.6,7 
On the other hand, large animal stroke models are both more laborious and more expensive to 
utilize than rodent models. Budgetary limitations often restrict sample sizes in large animal 
experiments, which limits statistical power.8 Hence, it is essential to conduct large animal 
experiments with highest methodological rigor and to predefine precise endpoints that can be 
assessed with sufficient statistical power to take full advantage of the translational value of 
large animal stroke models.  
Little is known about the methodological rigor and quality of large animal stroke 
experiments. We performed a systematic review and quality assessment of studies using large 
animal stroke models. Our quality analysis was based on the Stroke Therapy Academic Industry 
Roundtable (STAIR)9,10 and Animals in Research: Reporting In Vivo Experiments (ARRIVE) 
guidelines.11 Based on the obtained results, we also provide suggestions for methodological 
improvements in large animal stroke research.
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2. Material & Methods
2.1. Study selection
         Literature research was performed by the first author (L.K.). L.K. was supported by E.M., 
a professional librarian with extensive experience in systematic literature research who helped 
with designing the search strategy. The two last authors (S.M. and J.B.) were consulted by L.K. 
in case of any doubts or questions when extracting information from the literature. Intra-
assessor reproducibility was not assessed.
2.1.1. Search strategy
We conducted a systematic search for preclinical large animal experiments in stroke using 
the Medline via Ovid from Wolters Kluwer and Science Citation Index Expanded via Web of 
Science from Clarivate Analytics data bases. 
The initial search was conducted on September 26th, 2017, and an update was performed 
on August 9th, 2019. Data base entries between January 1st, 1990 and August 8th, 2019 were 
covered.
Search terms were “large animal” (including any relevant species, e.g. dogs, cats, pigs, 
rabbits, non-human-primates, sheep, goats, etc.) and “ischemic stroke” (involving for instance 
“brain ischemia” OR “ischemic neuronal injury” OR “thrombembolic stroke” OR 
“cerebrovascular disorders”). In the search strategies we combined the aspects large aninals 
and ischemic stroke with AND. Within each aspect we generally combined keywords, their 
synonyms and – for indexed citations of MEDLINE – controlled for vocabulary terms (Medical 
Subject Headings) using the operator OR. Detailed search strategies are provided in 
Supplementary Tables 1 and 2. The search process was conducted and results were recorded 
according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines (Figure 1A).
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2.1.2. Inclusion and exclusion criteria 
We included preclinical large animal studies conducted and published between 1990 and 
2019 that report investigations of therapeutic and/or diagnostic procedures for ischemic stroke. 
The studies needed to compare at least two groups, i.e. one in which a new procedure 
(therapeutic or diagnostic) is tested by comparing it to a second group being subjected to a 
standard or reference procedure (“control group”). Only studies in English were included.
We excluded studies focusing on diseases other than ischemic stroke, using small animal 
(e.g., rodent) models, clinical trials, in vitro studies, reviews, and meta-analyses. Purely 
descriptive studies only reporting a method or procedure, or non-controlled experiments (e.g., 
cases series) were also excluded. 
2.2. Data extraction
2.2.1.Basic study characteristics and impact factor 
First, study meta-data were extracted. Those included information on species, type of 
intervention, year of publication and region of origin (North America, Europe, Asia & Oceania), 
aim of evaluation (e.g., safety, feasibility), the stroke model used, study duration and 
information on investigation of dose-response-relationship (if applicable), compliance with 
animal welfare regulations, subject health condition prior to enrolment, animal housing 
conditions, and additional veterinary care.
Second, we documented the impact factor (IF) of the journal in which the study results 
were published, measured in the year of publication. IFs were identified via the annual 
Thomson Reuters Journal Impact Factor report. Where the IF could not be retrieved for the 
required year, we contacted the respective journal and asked to provide the IF for the particular 
year(s).
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2.2.2. Group sizes
We further extracted the number of subjects in experimental groups for each species. 
Group sizes were obtained for control and the diagnostic or therapeutic procedure group(s). 
2.3. Analysis
2.3.1. Assessment of Reporting Quality
We designated a scale that was applicable to both, diagnostic and therapeutic procedures, 
to assess study quality (Table 1). The quality score includes central STAIR and ARRIVE 
criteria, supplemented by additional quality items. The score comprised four categories, 
containing 6 items each. Category 1 addresses reporting of study subject details and welfare, 
category 2 covered the reporting of details on study design, category 3 addressed internal study 
validity, and category 4 assessed quality of outcome analysis and reporting. Each study was 
assigned a score from 0 (lowest quality) to 24 (highest quality), with each category having a 
quality value of 0 (lowest quality) to 6 (highest quality).
[Table 1 about here]
2.3.2. Additional aspects influencing study quality 
We further investigated whether study quality improved after the implementation of the 
STAIR guidelines in 1999, and their update in 2009.9,10 We also analyzed differences in quality 
with respect to species, region of study origin, and type of investigation (i.e., assessment of 
neuroprotectives, thrombolytics, cell therapies, diagnostics, and others). Furthermore, we 
evaluated possible associations between the quality score and IF. 
Page 39 of 68 Journal of Cerebral Blood Flow and Metabolism
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
7
2.3.3. Group sizes
Where a study reported more than one procedure group, they were all counted 
individually (maximum number was n=10). Average group sizes were calculated for control 
and procedure groups(s) for each species. We compared total group size (control plus procedure 
groups) across species as well as control and procedure groups separately.
2.4 Statistics 
All statistical analyses were performed using GraphPad PRISM 5 Software. Statistical 
significance was determined as p<0.05. Statistical significance was indicated with a single 
asterisk (*) at p<0.05, or a double asterisk (**) at p<0.01, respectively. Median as well as IQR 
(interquartile range including 25% and 75% quartiles) were documented. Comparisons between 
two groups were performed using the Wilcoxon signed rank test for non-parametric data to 
conservatively account for relatively small sample sizes. In case more than two groups were 
compared, the Kruskal-Wallis test was used, followed by Dunn`s correction for multiple 
comparisons. Spearman’s correlation analysis was performed to evaluate associations between 
quality score and IF. Group sizes were analyzed by ANOVA on ranks (no normal distribution 
of data) followed by Dunn's multiple comparison test.
3. Results 
3.1. Data set and year of publication
Initial and update searches identified a total of 10282 manuscripts being reduced to 8093 
after elimination of duplicates. (Figure 1A; a list of all studies included can be found in the 
supplementary material). A total of 208 studies were included in final analysis after screening 
abstracts and full text according to preset inclusion and exclusion criteria (Figure 1A). Results 
of basic study characteristics are shown in Table 2.
Analysis of publication output per year revealed that the number of large animal 
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8
experiments published from 1990 to 2014 generally decreased from n=56 in 1990-1994 to n=21 
in 2010-2014 (Figure 1B). However, there was a steep increase in published studies from 2015, 
reaching an all-time high (n=40) even though studies published in late 2019 are not yet included 
in our search strategy. This might be related to the milestone evidence for clinical benefit 
publication of mechanical thrombectomy in large vessel occlusion stroke by the publication of 
five randomized controlled trials in 2015 that may have sparked new interest in the field and an 
increased demand or large animal models to investigate related procedures.12,13
[Figure 1 about here]
[Table 2 about here]
3.2. Study Quality
The overall median quality score was 11 (range 3 to 22; IQR: 4 (9-13)) out of 24. The 
median quality score in the first category (reporting of study subject details and welfare) was 2 
out of 6 (range 1 to 5; IQR: 1 (1-2)). The second category (study planning quality) also reached 
a median quality score of 2 (range 1 to 6; IQR: 1 (2-3)). The third category (study conductance 
quality) had a median score of 3 (range 0 to 6; IQR: 2 (2-4)). Category 4 (result reporting and 
analysis quality) had a median quality score of 4 (range 0 to 6; IQR: 1 (2-4)). A significantly 
lower number of quality criteria were fulfilled in category 1 in comparison to the others 
(p<0.05).
3.2.1. Study subject details and welfare (category 1)
All studies reported the species used, but only 146 studies (70.2%) reported that the study 
was approved by responsible animal welfare authorities. Sex and age were reported by 31 
studies (15.0%). Sex only was reported by 153 (73.6%), while age was not reported solely. The 
pre-study health status was reported by only 12 studies (5.8%). Medication details including 
Page 41 of 68 Journal of Cerebral Blood Flow and Metabolism
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
9
the use of companion medication (e.g., analgetics, antibiotics) was reported in only 20 studies 
(9.6%). Comorbidities were not reported by any study.
3.2.2.Study planning (category 2)
Working hypotheses were reported in 207 (99.5%) studies. However, primary study 
endpoints were nominally determined in only 10 studies (4.8%). 135 (64.6%) studies reported 
that the study rationale was based on earlier small animal (n=79; 38.0%) or in vitro studies 
(n=25; 12.1%), or both (n=16; 7.7%). Effect size estimation and a priori sample size calculation 
can be performed based on such data. However, only 27 studies (13.0%) actually reported an 
estimation of effect size and a priori sample size calculation. A specific primary working 
hypothesis explicitly referring to previous in vitro and/or in vivo studies was reported in 18 
studies (8.7%). Inclusion and exclusion criteria were reported in 104 studies (50.0%), but only 
2 studies (1.0%) determined these criteria a priori.
3.2.3.Study conductance (category 3) 
Randomization was reported in 116 studies (55.8%), and allocation concealment was 
reported in 59 cases (28.4%). 104 studies (50.0%) reported blinded outcome assessment. 
Measurement of physiological parameters was reported in 165 cases (79.3%). The most 
frequently monitored parameters included mean arterial pressure (systemic), temperature, 
blood gases, blood pH, and exhalation gases. 186 studies reported appropriate outcome analysis 
modalities (89.4%; information on inappropriate analysis modalities are provided in 
Supplementary Table 3). These included survival rate (n=2; 1.0 %), functional outcome (n=67; 
32.2%), infarct size (n=46; 22.1%, as determined by appropriate methods such as imaging or 
histology), other imaging (n=90; 43.3%) or histology (n=61; 29.3%) endpoints, clinical 
chemistry (n=52; 25.0%), general pathology (n=24; 11.5%) or both (n=18; 8.7%). Only a 
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fraction of studies that recorded physiological parameters finally analyzed those (n=52; 25.0%). 
100 studies (48.1%) reported verification of infarct induction during intervention.
3.2.4.Result reporting and analysis (category 4)
168 studies (80.8%) adequately reported relevant data and findings in form of detailed 
tables or graphs. However, data were almost exclusively reported as means or medians. 
Individual data points were only provided by 16 studies (7.7%). Drop outs and excluded 
subjects were reported in 105 studies (50.5%). Application of appropriate statistical tests was 
reported in 192 studies (92.3%). 16 studies incompletely reported statistical analysis and, for 
example lacking information regarding statistical tests applied including post hoc tests. 91 
studies (43.8%) described potential sources of error and bias in the experiment, while 115 
(55.3%) reported limitations such as small sample size or that it was impossible to perform 
randomization. A conclusion fully justified by study findings was given in by most, but not all 
reports (n=190; 91.3%).
3.3. Additional influences on study quality
3.3.1. Study quality versus origin, species and type of intervention
Total median quality score was highest in studies from North America (Median: 12; IQR: 
10-14), statistically different from studies conducted in Asia & Oceania (Median: 10; IQR: 
(8.75-12) or  Europe (Median: 10; IQR: 8-11.75; p=0.0011 Figure 2A). Analysis of individual 
quality categories revealed no differences in category 1 (Figure 2B) but North American studies 
had statistically significantly higher scores in quality categories 2 (Median: 2.5; IQR: 2-3) and 
3 (Median: 4; IQR: 3-5) than their European counterparts (Median: 2; IQR: 1-2; p<0.01; Figure 
2C). Furthermore, North American studies were superior to Asian & Oceanian studies in 
category 3 (Median 3; IQR: 2-4; p<0.01; Figure 2D). We did not find statistically significant 
differences regarding category 4 (Figure 2E). Quality scores were neither influenced by species 
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used (Figure 2F) nor by the types of intervention (Figure 2G). Overall differences in median 
quality score in species varied significantly without any specific intergroup difference. 
[Figure 2 about here]
3.3.2. Study quality in the post-STAIR era
Methodological quality significantly improved after introduction of the STAIR guidelines in 
1999 (1990-1999 pre-STAIR median: 10, IQR: 8-12; post-STAIR median: 12, IQR: 9-15; 
p<0.01; Figure 2H). We also compared quality scores of studies published prior to the first 
STAIR guidelines to quality scores of studies published in the time between the first STAIR 
guideline publication and the 2009 update (2000-2009; median: 11; IQR: 9-13), and to scores 
of studies published after the STAIR 2009 update (2010-2019; median: 13.; IQR: 10-15). 
Quality scores of studies published after the STAIR 2009 update were higher than those of 
studies published before the initial STAIR guideline publication (1990-1999; p<0.01). They 
were also higher than quality scores of studies published after the first publication of STAIR 
guidelines and prior to the 2009 update (2000-2009; p<0.05; Figure 2I).
Improvements were particularly evident in categories 1 and 4.  In category 1, quality 
scores were lower in pre-STAIR studies (1990-1999; median: 1, IQR: 1-2) as compared to 
studies published after the first publication of STAIR guidelines and prior to the 2009 update   
(2000-2009; median: 2; IQR: 1.25-2) and to studies published after the 2009 update (2010-
2019; median: 2; IQR: 2-3; p<0.01). There was also a significant difference in category 1 
quality scores of studies published after the 2009 update to studies published between 2000 and 
2009 (p<0.01).  In category 4, quality scores of studies published after the 2009 STAIR update 
(2010-2019; median: 4; IQR: 3-5) were higher than those of studies published before the STAIR 
guidelines introduction (1990-1999; median: 3; IQR: 2-4) and those of studies published 
between 2000 and 2009 (median 3; IQR: 2-4; p<0.01 each). 
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3.3.3. Study quality versus impact factor
The IF was available for 172 studies (82.7%). We could not retrieve the IF for the 
remaining studies or no IF yet assigned on the particular journal in the year of publication 
(n=36; 17.3%). These latter studies were therefore excluded from the following analyses. 
Median IF was 3.3 (range 0.1 to 41.6; IQR: 2-4.6). Correlation analysis showed a statistically 
significant positive relationship between the total quality score and the IF (r=0.2802; p<0.01, 
alpha=0.05; Figure 3). We also correlated each quality score category with the IF and found 
that quality scores in all individual categories positively correlated with the IF (category 1: 
r=0.1851; p<0.05; category 2: r=0.1653; p<0.05; category 3:  r=0.1858; p<0.05; category 4: 
r=0.2297; p<0.01; Supplementary Figure 1). 
Figure 3 about here
3.3.4. Group sizes
Average group sizes across species are given in Table 3. Analysis of group sizes 
revealed that total (combined control and procedure) group size was largest in rabbits as 
compared to pigs (p<0.01), sheep and primates (p<0.05 each). Total group sizes in cats were 
larger than those in sheep (p<0.05; Figure 4A). Accordingly, control groups were largest in 
rabbits as compared to pigs (p<0.05) and primates (p<0.01; Figure 4B), while procedure groups 
were largest in rabbits as compared to pigs (p<0.01; Figure 4C).    
[Table 3 about here]
[Figure 4 about here]
4. Discussion
Systematic bias may cause over- or underestimation of study results.3 Quality items such 
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as randomization, allocation concealment, and blinded assessment improve internal validity 14, 
but are often neglected in small animal studies.3, 15, 16
Large animal models are believed to offer significant benefits for translational stroke 
research. They have  higher anatomical similarity to the human brain17 and to the 
cerebrovascular system.6, 7, 18 Another benefit is the potential to use these models in experiments 
closely mimicking a human clinical situation, and applying the same medical techniques and 
equipment for diagnostic and therapeutic interventions that would be used in human patients.7, 
19 Moreover, physiological characteristics of large animal models including heart and 
respiratory frequency, blood pressure as well as pharmacodynamic and pharmacokinetic 
profiles are similar to humans.20, 21 However, in view of these advantages, large animal studies 
require much greater efforts and resources. It is therefore important that quality in large animal 
studies is as high as possible to efficiently utilize the advantages large animal models offer for 
translational research.
Overall, we found that methodological quality in large animal stroke studies was 
mediocre. Although quality generally improved significantly over the last decades and 
potentially due to the 1999 publication and 2019 update of the STAIR criteria, our analysis 
revealed some important shortcomings. Improvements are needed in reporting study subject 
details and welfare (quality score category 1). Aspects such as sex and age, pre-study health 
conditions, and medications should be reported routinely for optimal study transparency and 
reproducibility, and transferability of study results.9 The lack of comorbid large animal models 
is not surprising. Comorbidities are difficult to simulate in outbred large animal models as they 
occur due to age, distress, malnutrition and other factors according to the human situation, and 
can take significant time in large animals to develop. Research on models exhibiting 
comorbidities may remain a domain of small animal research. Nevertheless, any spontaneously 
occurring comorbidities being diagnosed in large animals used for research should be reported.
Working hypotheses were reported in almost all studies (99.5%), but often without any 
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obvious influence on study design. For instance, only 4.8% of the studies defined and reported 
primary endpoints, while analysis of expectable effect size and a priori sample size calculation 
were performed in few cases only (13.0%). This may severely limit the translational benefits 
of large animal models since study results may be hard to interpret based on potentially poor 
statistical power. Given the significant resources required to perform large animal studies, 
considering these aspects is essential. On the other hand, determination of effect size can be 
challenging when previous research data is lacking or not entirely applicable. In these cases, 
we recommend to perform large animal pilot studies that may help to assess basic 
characteristics in the respective model, such as variability of infarct size and its impact on the 
envisioned primary endpoint.
While half of the studies reported inclusion and exclusion criteria (50.0%), almost none 
(1.0%) applied them a priori. Defining inclusion and exclusion criteria during or after the study 
is believed to be a major source of bias, particularly when a study is conducted in non-blinded 
fashion. Hence, such bias can unfortunately not be excluded for most studies we analyzed. 
Important quality aspects such as randomization (55.8%), allocation concealment 
(28.4%), and blinded assessment of outcome (50.0%) were more frequently reported in large 
animal studies as compared to small animal stroke experiments (randomization: 33.3%; blinded 
assessment of outcome: 44.4%,16 allocation concealment: 25.9%; randomization, allocation 
concealment and blinded assessment of outcome: 24.1.%.22 Nevertheless, the number of studies 
not reporting those is still remarkably high in particular since blinding and randomization 
should be minimum standard quality assurance procedures in confirmative stroke research23 to 
which almost all large animal studies aim to contribute.
 Imaging techniques such as magnetic resonance imaging, computed tomography, and 
angiography (43.5%) as well as physiological monitoring (80.4%) were utilized relatively 
frequently. This is a positive aspect since large animals are particularly suitable for clinical 
imaging techniques while thorough physiological monitoring creates meaningful information 
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that may warrant subject in- or exclusion. However, verification of infarct induction (only 
reported in 48.1%) as well as infarct size should be conducted thoroughly and routinely to avoid 
the risk of increasing inter-subject/-study/-group variability, further reducing statistical power 
of an experiment. Parameters such as cerebral blood flow reduction for verification of infarct 
induction was documented by only 7.2% of studies. This is surprising since these parameters 
are relatively easy to determine in large animals, while clinical imaging techniques may be used 
to confirm the induced lesion directly.21
Large animals are suitable for long-term studies including functional endpoint 
assessment. However, we only found a relatively low percentage (6.7%) of studies being 
conducted for more than one month, the minimum follow-up period recommended by the 
STAIR guidelines for functional endpoints. Next to costs, this may be due to the selection of 
other primary endpoints such as safety or efficacy of recanalization methods which can be 
assessed more rapidly. However, experimenters who wish to assess behavioral endpoints 
should take into consideration that functional consequences of stroke in large animals can be 
more heterogeneous than in rodent models, and may develop over longer time spans.24
We recognized significant improvements in methodological quality since the publication 
of the first STAIR guidelines in 1999, and in particular after the STAIR guideline update in 
2009. Comparable improvements were reported for small animal stroke studies from 2010 to 
2013.25 These findings indicate the positive impact of specific good research practice 
guidelines, which should be advanced continuously as evidenced by the recent 2019 STAIR 
guideline updates.26 In contrast to previous findings in small animal studies,27 we also identified 
positive association (r=0.2802; p<0.01) between study quality and publication in high-impact 
journals. In particular, total quality score as well as quality scores in all single categories 1-4 
significantly correlated with higher IF. This is an encouraging result since all these categories 
include items being important to prevent bias. These items are hence indispensable for a valid 
and transparent exchange of information between researchers. 
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          Group sizes were significantly larger in rabbits as compared to other species. This is not 
surprising as rabbits are the smallest and cheapest of all large animal species what allows for 
larger group sizes. Importantly, group sizes in primates are generally not different to that of 
other species. This does not mean that group sizes were sufficient for each research question, 
but shows that costs related to primate experiments did not prevent the same group sizes as seen 
in other large animal species despite rabbits.
Our study has a number of limitations. We applied a predefined search strategy and 
protocol being developed together an expert in literature meta-analyses (E.M.) and experts in 
stroke research (J.B., S.M.). However, search strategy and protocol were not registered (ex ante 
protocol). Data extraction was not done in duplicate, but senior experts were consulted in all 
doubtful cases. Intra-assessor reproducibility was not assessed. Moreover, we did not 
discriminate between studies focusing on therapeutic and diagnostic procedures. Large animal 
models provide a number of benefits over rodent models for diagnostic studies due to the larger 
brain size and in particular when clinical imaging is used.33 However, those studies are often 
exploratory in nature. Since quality demands are different (and a bit lower) than in confirmative 
studies, those imaging-related studies would perform normally worse but still can contribute 
invaluably to their respective field.34 Finally, we did not include a number of insightful imaging 
studies because they did not conduct a formal inter-group comparison.35,36,37,38
5. Conclusions and Recommendations
Although large animal models offer a offer a number of clear advantages for translational 
stroke, we found that they have similar shortcomings to small animal models, limiting this 
benefit. Therefore, we derived a number of recommendations to address these limitations but 
are, at the same time, relatively easy to implement.
5.1 Study planning and preparation
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Large animal stroke studies are mostly confirmative studies. Therefore, study planning 
should be based on high quality standards applied for randomized controlled clinical trials 
(RCTs) when possible. Key elements of RCT planning and design such as a priori sample size 
calculation and endpoint definition should be conducted.23 We encourage to involve 
statisticians already in early planning steps to optimize study design.28 Study planning can also 
be supported by specific software tools. For instance, the National Centre for the Replacement, 
Refinement and Reduction of Animals in Research provides a freeware called Experimental 
Design Assistance (https://eda.nc3rs.org.uk), which is free to use and was built to guide 
researchers through their study planning.29 Since optimal sample sizes may not be achieved for 
all endpoints, it is important to clearly define the most appropriate primary study endpoint, and 
to power the study properly. Collaboration between research teams in form of peer quality 
checks and validation of study design can highly increase objectivity and validity of a study.30 
Inter-group collaboration and transfer of experience can also help to handle very complex 
models and/or experimental setups, helping to reduce inter-subject variability negatively 
affecting statistical power. Confirmative studies might be preregistered to maximize 
transparency.39 
5.2 Effect size estimation and pilot trials
Collecting valid information from previous research is essential for reliable effect size 
estimation. If such data are not available, pilot studies may be helpful for at least basically 
estimating variability of stroke impact and outcome in the model. In case previous experience 
with a particular model is low, variability is more likely to be higher and effect size is more 
likely to lower in such pilot trials.  This will contribute to more conservative study planning 
since sample sizes calculated based on that information will be higher.. An important side effect 
of pilot trials is experimenter training which limits experimenter-caused endpoint variability 
(see below) in the main experiment. In addition, meta-analyses can help to collect relevant 
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information on effect size or regarding a specific research question from related fields.31
5.3 Reducing the effect of sample size limitations and endpoint variability
Financial and logistical restrictions often impact sample and group sizes in large animal 
experiments. This is an understandable limitation which is difficult to overcome. Selection of 
a proper and relevant endpoint that can be adequately powered with respected to the addressed 
research question is therefore important to minimize the risk for low statistical power. Of note, 
some endpoints often used in studies assessing therapeutic interventions including infarct size 
and functional deficits, exhibit a higher variability in large animal models than in rodent. This 
makes comparison of absolute data more difficult.24 Relative analysis of repeatedly assessed 
endpoints, i.e. in comparison to the individual initial infarct size and/or functional deficit can 
efficiently compensate for such variability. Repeated assessments also allow calculating the 
area under the curve for particular endpoints. This may provide a benefit in statistical power to 
identify whether a real outcome benefit is present over time. However, this comes at the cost 
of temporal resolution: it cannot be concluded exactly when this benefit became evident. There 
is also preliminary evidence for fast and slow stroke progressors in large animals, indicating 
different collateral status and somewhat resembling the human situation, but further 
contributing to inter-subject variability. It is recommended to consider this fact when planning 
an acute stroke study.32
In experiments of highly similar design, controls may be pooled. Of note, this counteracts 
randomization and therefore requires extremely thorough validation of comparability of control 
subjects from different experiments/sources. If comparability is thoroughly proven, this may 
help to increase statistical power, but the limitations of this approach and potentially resulting 
bias need to be discussed transparently and in detail when publishing results. 
The possibility to repeatedly collect a broad spectrum of physiological data should be 
utilized where possible, as deviation from normal parameter ranges may explain variability and 
warrant post-hoc exclusion of subjects in single cases.
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5.4 Study duration and documentation
We recommend considering long-term experiments whenever meaningful and possible 
and meeting animal welfare requirements. Even though long-term experiments involve greater 
efforts, the amount of data collected for individual subjects may be much higher, providing a 
better overall picture on the assessed intervention. Documentation should be as transparent as 
possible because transparency is not challenging or laborious, but contributes significantly to 
increased scientific rigor, reproducibility, and unbiased study result interpretation. 
Methodological limitations including lacking quality aspects due to good reason should be 
clearly stated as this allows bet er interpretation of positive, neutral and negative study results. 
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Figure legends
Figure 1. Overview on quantitative search results and frequency of large animal 
experiments in stroke research since 1990.
(A) Flow diagram of publication identification. N = Number of publications. Records 
were excluded after screening title and abstracts. Full-text articles were then screened and 
excluded for a priori determined reasons. (B) Timeline of publication in large animal stroke 
research (1990-2019): The increase of large animal stroke studies in the last years is potentially 
due to the breakthrough in recanalization therapies, prompting a number of follow-on 
translational studies utilizing large animal stroke models.
Figure 2. Influence of study origin and STAIR criteria publication on study quality. 
(A) Total quality score, (B) Category 1: Reporting of study subject and animal welfare, 
(C) Category 2: Study planning quality (North America vs. Europe p<0.01), (D) Category 3: 
Study conductance quality (North America vs. Asia & Oceania p<0.01), (E) Category 4: Result 
reporting and analysis quality (North America vs. Europe p<0.01), (F) Influence of species, (G) 
Improvement in total methodological quality since the publication of the first STAIR criteria 
in 1999 (p<0.01), (H) Improvement in total methodological quality since the publication of the 
first STAIR criteria in 1999 comparing to their amendment in 2009 (2010-2019 vs. 1990-1999 
p<0.01, and 2010-2019 vs. 2000-2009 p<0.05),  (I) Influence of type of intervention. Horizontal 
lines and whiskers indicate the median with lower and upper 95% CI. *p<0.05; **p<0.01.
Figure 3. Association between total quality score versus impact factor.
Scatterplot shows correlation between quality score and IF (p<0.01). Number of included 
studies is 172, no IF could be retrieved for 36 studies. The latter studies were excluded from 
this analysis.
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Figure 4. Group sizes across species.
         (A) Total group sizes were largest in rabbits as compared to pigs (p<0.01), primates and 
sheep (p<0.05 each). (B) Control group sizes were larger in rabbits as compared to primates 
(p<0.01) and pigs (p<0.05). (C) Procedure group sizes were larger in rabbits as compared to 
pigs (p<0.01). Horizontal lines and whiskers indicate the median with lower and upper 95% CI. 
*p<0.05, **p<0.01.
Tables
Table 1. Quality score items. 
Category 1: Reporting of study subject 
details and welfare
Category 2: Study planning quality
Item Score point 
allocation
Item Score point 
allocation
1. Animal protocol 
approved
Reported 
yes=1/no=0
1. Study hypothesis Reported 
yes=1/no=0
2. Species Reported 
yes=1/no=0
2. A priori endpoint 
definition
Reported 
yes=1/no=0
3. Sex and Age Reported 
yes=1/no=0
3. A priori sample size 
calculation
Reported 
yes=1/no=0
4. Pre-Study Health Reported 
yes=1/no=0
4. Reference to previous 
studies
Reported 
yes=1/no=0
5. Comorbidities Reported 
yes=1/no=0
5. Inclusion/Exclusion 
criteria
Reported 
yes/no=0
6. Adequate 
medication
Reported 
yes=1/no=0
6. Effect size/Treatment 
effect
Reported 
yes=1/no=0
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Category 3: Internal study validity Category 4: Outcome analysis and 
reporting
Item Score point 
allocation
Item Score point 
allocation
1. Blinding Reported 
yes=1/no=0
1. Individual data points Reported
yes=1/no=0
2. Randomization Reported 
yes=1/no=0
2. Drop outs/Excluded 
subjects
Reported 
yes=1/no=0
3. Allocation 
concealment
Reported 
yes=1/no=0
3. Appropriate statistical 
tests
Used 
yes=1/no=0
4. Physiological 
parameters
Measuring reported 
yes=1/no=0
4. Potential error sources Reported 
yes=1/no=0
5. Analysis 
modalities
Appropriate 
modalities reported# 
yes=1/no=0
5. Study/Methodological 
limits
Reported 
yes=1/no=0
6. Infarct induction 
confirmation
Reported 
yes=1/no=0
6. Justified conclusion 
given##
Provided 
yes=1/no=0
#analysis modalities were considered appropriate when being sufficient to assess the 
respective research question or endpoint (see Supplementary Table 3 for details).
##conclusion was considered justified when supported by correctly analyzed results.
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Table 2. Basic Characteristics of included Animal Experimental Studies.
Item Frequency (%) Item Frequency (%) Item Frequency (%)
Species Type of intervention Study duration
Rabbit n=96 (46.1%) Neuroprotectives n=113 (54.3%) Acute phase (<24h) n=139 (66.9%)
Cat n=43 (20.7%) Thrombolytics n=52 (25.0%) 1-3 days n=26 (12.5%)
Dog n=16 (7.7%) Cell therapies n=7 (3.4%) <1 week n=15 (7.2%)
Non-Human-Primate n=32 (15.4%) Diagnostics n=15 (7.2%) <1month n=14 (6.7%)
Pig n=19 (9.1%) Others# n=21 (10.1%) >1 month n=14 (6.7%)
Non-Human-Primate & 
Rabbit
n=1 (0.5%)
Sheep n=1 (0.5%)
Region Primary endpoint Stroke model
North America n=134 (64.4%) Efficacy n=162 (77.9%) Transient n=120 (57.7%)
Europe n=24 (11.5%) Safety n=12 (5.8%) Permanent n=76 (36.5%)
Asia/Oceania n=50 (24.1%) Feasibility n=22 (10.5%) Transient +Permanent n=1 (0.5%)
Safety + n=1 (0.5%) Not reported n=11 (5.3%)
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Feasibility
Safety + Efficacy n=11 (5.3%)
Further information
Additional veterinary care 
reported 
n=11 (5.3%)
Dose-response 
relationship reported
n=30 (14.4%)
Compliance with animal 
welfare regulations 
reported 
n=128 (61.5%)
Pre-study quarantine 
reported
n=3 (1.4%)
Animal housing 
conditions## reported
n=23 (11.1%)
#these included hypothermia (n=7), hemodilution (n=5), facial nerve stimulation (n=2), hyperglycemia, retrograde transvenous perfusion, crosslinked 
hemoglobin transfusion, alkalinization of systemic pH, omental transposition, induced hypertension, RIPC (short term remote ischemic 
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postconditioning) (n=1 each)
##e.g., feeding, light/dark circle, single or grouped housing
Table 3. Median experimental group sizes across large animal species.
Non-human primate Rabbit Dog Cat Sheep Pig
C P T C P T C P T C P T C P T C P T
7.4
(1-24) 
n=35
6.3
(2-17) 
n=64
6.6 
(1-24) 
n=99
12.4 
(2-50) 
n=108
10.0 
(2-57) 
n=267
11.0 
(2-57) 
n=375
7.1 
(5-10) 
n=15
9.0
(1-16) 
n=25
8.3 
(1-16) 
n=40
8.7
(2-17) 
n=45
8.6 
(3-18) 
n=77
8.6 
(2-18) 
n=122
6 
(6) 
n=1
4.25 
(3-6) 
n=4
4.2 
(3-6) 
n=5
5.8
(2-11) 
n=16
6.4
(1-10) 
n=45
6.2 
(1-11) 
n=60
C: control group; P: procedure group(s); T: total (combined) groups. Ranges (min.-max.) are given in brackets. n describes numbers of groups 
throughout the included literature.
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Figure 1. Overview on quantitative search results and frequency of large animal experiments in stroke 
research since 1990. 
(A) Flow diagram of publication identification. N = Number of publications. Records were excluded after 
screening title and abstracts. Full-text articles were then screened and excluded for a priori determined 
reasons. (B) Timeline of publication in large animal stroke research (1990-2019): The increase of large 
animal stroke studies in the last years is potentially due to the breakthrough in recanalization therapies, 
prompting a number of follow-on translational studies utilizing large animal stroke models. 
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Figure 2. Influence of study origin and STAIR criteria publication on study quality. 
(A) Total quality score, (B) Category 1: Reporting of study subject and animal welfare, (C) Category 2: 
Study planning quality (North America vs. Europe p<0.01), (D) Category 3: Study conductance quality 
(North America vs. Asia & Oceania p<0.01), (E) Category 4: Result reporting and analysis quality (North 
America vs. Europe p<0.01), (F) Influence of species, (G) Improvement in total methodological quality since 
the publication of the first STAIR criteria in 1999 (p<0.01), (H) Improvement in total methodological quality 
since the publication of the first STAIR criteria in 1999 comparing to their amendment in 2009 (2010-2019 
vs. 1990-1999 p<0.01, and 2010-2019 vs. 2000-2009 p<0.05),  (I) Influence of type of intervention. 
Horizontal lines and whiskers indicate the median with lower and upper 95% CI. *p<0.05; **p<0.01. 
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Figure 3. Association between total quality score versus impact factor. 
Scatterplot shows correlation between quality score and IF (p<0.01). Number of included studies is 172, no 
IF could be retrieved for 36 studies. The latter studies were excluded from this analysis. 
304x222mm (96 x 96 DPI) 
Page 67 of 68 Journal of Cerebral Blood Flow and Metabolism
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
Figure 4. Group sizes across species. 
        (A) Total group sizes were largest in rabbits as compared to pigs (p<0.01), primates and sheep 
(p<0.05 each). (B) Control group sizes were larger in rabbits as compared to primates (p<0.01) and pigs 
(p<0.05). (C) Procedure group sizes were larger in rabbits as compared to pigs (p<0.01). Horizontal lines 
and whiskers indicate the median with lower and upper 95% CI. *p<0.05, **p<0.01. 
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